Giant Cell Arteritis Epidemiology Forecast 2025-2034

Giant cell arteritis also referred to as temporal arteritis. It is a form of vasculitis (inflammation of blood vessels), which primarily affects the medium and large arteries, particularly those in the head and neck region. It is the most common vasculitis in adulthood with an annual incidence of 1/5,000-1/17,000 adults over 50 years old and is more frequent in northern European population.

Giant Cell Arteritis Epidemiology Forecast Report Coverage

The “Giant Cell Arteritis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of giant cell arteritis. It projects the future incidence and prevalence rates of giant cell arteritis across various populations. The study covers age, gender, and type as major determinants of the giant cell arteritis-affected population. The report highlights patterns in the prevalence of giant cell arteritis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of giant cell arteritis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Giant Cell Arteritis Disease Overview

Giant cell arteritis is a vasculitis which primarily affects the large and medium arteries in the head and neck region, affecting people over 50 years of age. Headaches, sore scalps, jaw pain, and vision problems are among the symptoms. Aneurysm formation and vascular remodeling may result from the granulomatous nature of the disease, which also contributes to the loss of vascular smooth muscle cells and elastic fibers. Ischemic complications are exacerbated by lumen occlusion and intimal hyperplasia. The diagnosis process includes blood tests, temporal artery biopsy, and clinical evaluation.

Giant Cell Arteritis: Treatment Overview

High-dose corticosteroids, like prednisone, are used to treat giant cell arthritis as they rapidly reduce inflammation and avoid consequences like vision loss. An IL-6 receptor blocker called tocilizumab may be used to reduce steroid dependence or in cases that are refractory. To reduce vascular risk, low-dose aspirin is frequently added. It is advised to take calcium and vitamin D supplements to prevent osteoporosis brought on by steroids. Because of the possibility of relapse and adverse drug reactions, long-term monitoring is necessary.

Epidemiology

The giant cell arteritis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for giant cell arteritis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for giant cell arteritis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the National Health Institute, the lifetime risk of developing giant cell arteritis is estimated to be approximately 1% for women and 0.5% for men in the United States. The disease majorly affects patients older than 50 years of age, with the highest incidence observed in between 70 and 79.
• According to a research article by BMC, the incidence of giant cell arteritis was 10.00 cases per 100,000 people over 50 years old. Of the 3569 citations identified, 107 were included.
• According to a cohort study conducted by the National Institute of Health in 2023, giant cell arteritis was diagnosed in 28 of 60 polymyalgia rheumatica patients (46%).
• According to a research article published by Rheumatology Advisor, giant cell arteritis is 2.5 times more common in women than in men, with a lifetime risk of 0.5% for men and 1% for women.

Country-wise Giant Cell Arteritis Epidemiology

The giant cell arteritis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Giant cell arteritis prevalence varies globally, being highest in Northern Europe and among populations of European descent, while its prevalence is less in regions like Asia, Africa, and the Middle East. Research studies suggest that the Scandinavian countries and Scandinavian individuals show the highest incidence rates, while lower rates are noted in regions like Asian, African American, Arabic, or Japanese populations. Moreover, around 40%-60% of patients with giant cell arteritis may also have polymyalgia rheumatica.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification of giant cell arteritis based on several factors.
• Giant Cell Arteritis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of giant cell arteritis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of giant cell arteritis epidemiology in the 8 major markets?
• What will be the total number of patients with giant cell arteritis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of giant cell arteritis in the 8 major markets in the historical period?
• Which country will have the highest number of giant cell arteritis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of giant cell arteritis during the forecast period of 2025-2034?
• What are the currently available treatments for giant cell arteritis?
• What are the disease risks, signs, symptoms, and unmet needs of giant cell arteritis?

This product will be delivered within 3-5 business days.